Endocrine Month in Review: July 2022

Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.

July 2022 Month in Review

1. Medicare Advantage Beneficiaries Less Likely to Receive Newer Diabetes Medications

New research from the University of Pittsburgh School of Medicine suggests Medicare Advantage patients with diabetes are more likely to receive preventive treatments, but less likely to be prescribed newer medications and more likely to have higher blood pressure and worse glycemic control than patients in Medicare Fee-For-Service programs.

2. North American Menopause Society Updates Hormone Therapy Guidance

Released on July 7, the 2022 hormone therapy position statement from the North American Menopause Society is 28 pages in length and has received endorsement from 20 international organizations, including the American Academy of Clinical Endocrinology.

3. Hormone Replacement Therapy Does Not Increase Breast Cancer Recurrence, Mortality in Survivors

Undergoing hormone replacement therapy for menopausal symptoms does not increase the risk of breast cancer recurrence in women treated for breast cancer, according to a new study of more than 8000 women.

4. Diabetes Can Increase Mortality, Morbidity in Acromegaly

New research from investigators in Sweden is providing clinicians with insight into the additional risk of mortality associated with a diagnosis of diabetes in patients with acromegaly.

5. Top FDA Approvals in Diabetes Care from the First Half of 2022

With the first 6 months of 2022 behind us, we compiled a list of the top approvals in diabetes care from the first half of the year. The list includes multiple approvals for CGM, a first-in-class agent, and an increased dose of a popular GLP-1 RA.

Click here for previous versions of our month in review.